Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the quinazolinamine class, with the molecular formula C19H19F3N4 and a molecular weight of approximately 360.38 g/mol[1][2][3]. It is primarily characterized as an experimental chemical probe or inhibitor targeting cyclin-dependent kinase 2 (CDK2), a key regulator of cell cycle progression. The compound has demonstrated inhibitory activity against CDK2, with an IC50 value of approximately 600 nM[1][2]. There are no known approved therapeutic indications or clinical uses for this molecule; it is mainly used in research settings to study cell cycle regulation and kinase inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-(3-aminophenyl)-N-tert-butyl-2-(trifluoromethyl)quinazolin-4-amine.